ETON
Eton Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$55.50
−2.75%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $0.34
- Revenue estimate
- $42.0M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- $0.43
- EPS estimate
- $0.11
- Revenue actual
- $37.6M
- Revenue estimate
- $27.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +9.7%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $68
- PT range
- $62 – $70
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | $0.11 | $0.43 | Beat 290.91% | $37.6M |
| May 14, 2026 | $0.10 | $0.05 | Miss -50.00% | $24.3M |
| Mar 19, 2026 | $0.12 | $0.05 | Miss -58.33% | $21.3M |
| Nov 6, 2025 | $0.16 | -$0.07 | Miss -143.75% | $22.5M |
| Aug 7, 2025 | -$0.01 | -$0.10 | Miss -900.00% | $18.9M |
| Mar 18, 2025 | -$0.02 | -$0.02 | In line | $11.6M |
| Aug 8, 2024 | -$0.07 | -$0.12 | Miss -71.43% | $9.1M |
| May 9, 2024 | -$0.07 | -$0.03 | Beat 57.14% | $8.0M |
| Mar 14, 2024 | -$0.04 | -$0.09 | Miss -125.00% | $7.3M |
| Nov 9, 2023 | -$0.10 | -$0.02 | Beat 80.00% | $7.0M |
| Aug 10, 2023 | -$0.09 | $0.15 | Beat 266.67% | $12.0M |
| May 11, 2023 | -$0.14 | -$0.10 | Beat 28.57% | $5.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026